-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 WDyYhKAsBRwHbfsIsI3K3i+VcMDwoKS/ZYvoSvTJElLxePBHBlf3Sq4xXCnWsNRr
 B0yog/J8K96oQDnCZfzuzg==

<SEC-DOCUMENT>0000842023-10-000023.txt : 20100803
<SEC-HEADER>0000842023-10-000023.hdr.sgml : 20100803
<ACCEPTANCE-DATETIME>20100803091227
ACCESSION NUMBER:		0000842023-10-000023
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20100803
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20100803
DATE AS OF CHANGE:		20100803

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TECHNE CORP /MN/
		CENTRAL INDEX KEY:			0000842023
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				411427402
		STATE OF INCORPORATION:			MN
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-17272
		FILM NUMBER:		10985905

	BUSINESS ADDRESS:	
		STREET 1:		614 MCKINLEY PL N E
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55413
		BUSINESS PHONE:		6123798854

	MAIL ADDRESS:	
		STREET 1:		614 MCKINLEY PLACE NE
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55413
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>k8q.txt
<DESCRIPTION>8-K
<TEXT>
                      SECURITIES AND EXCHANGE COMMISSION
                            WASHINGTON, D.C. 20549

                                FORM 8-K

                              CURRENT REPORT

                  PURSUANT TO SECTION 13 OR 15(d) OF THE
                     SECURITIES EXCHANGE ACT OF 1934

    Date of report (Date of earliest event reported): August 3, 2010

                            TECHNE CORPORATION
             (Exact Name of Registrant as Specified in Charter)


       Minnesota                     0-17272             41-1427402
(State or Other Jurisdiction       (Commission         I.R.S. Employer
of Incorporation)                  File Number)      Identification No.)

                614 Mckinley Place NE
                   Minneapolis, MN                       55413
       (Address of Principal Executive Offices)       (Zip Code)

     Registrant's telephone number, including area code:  (612) 379-8854

                              Not Applicable
      (Former Name or Former Address, if changed since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant under any
of the following provisions:

/ /   Written communications pursuant to Rule 425 under the Securities Act
      17 CFR 230.425)

/ /   Soliciting material pursuant to Rule 14a-12 under the Exchange Act
      (17 CFR 240.14a-12)

/ /   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

/ /   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))


<PAGE>



Item 2.02  Results of Operations and Financial Condition

A copy of the press release issued by Techne Corporation on August 3,
2010, describing the results of operations for the quarter and fiscal year
ended June 30, 2010 and its financial condition as of June 30,
2010, is attached hereto as Exhibit 99.1.

Segment information for Techne Corporation for the quarter and fiscal year
ended June 30, 2010 which has been included on Techne Corporation's
website (www.techne-corp.com), is attached hereto as Exhibit 99.2.

The information in this Form 8-K and the Exhibits attached hereto shall not
be deemed "filed" for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the "Exchange Act"), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference
in any filing under the Securities Act of 1933 or the Exchange Act, except as
expressly set forth by specific reference in such filing.


Item 9.01 Financial Statements and Exhibits

     (d) Exhibits

         99.1 Press Release dated August 3, 2010.

         99.2 Segment information for the quarter and fiscal year
              ended June 30, 2010.






                            SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


Dated: August 3, 2010                 TECHNE CORPORATION
                                      By: /s/ Thomas E. Oland
                                      ---------------------------
                                      Name: Thomas E. Oland
                                      Title: President and Chief
                                        Executive Officer



                          EXHIBIT INDEX

    Exhibit No. Description
    ----------- -----------
       99.1     Press release of Techne Corporation dated August 3, 2010.

       99.2     Segment information for Techne Corporation for the quarter
                and fiscal year ended June 30, 2010.

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>release610.txt
<DESCRIPTION>PRESS RELEASE DATED AUGUST 3
<TEXT>

             TECHNE CORPORATION RELEASES UNAUDITED FOURTH QUARTER
                      RESULTS FOR FISCAL YEAR 2010

Minneapolis/August 3, 2010/-- Techne Corporation's (NASDAQ: TECH)
consolidated net earnings for the quarter ended June 30, 2010 increased 2.0%
to $25.9 million or $.69 per diluted share compared with $25.4 million or
$.68 per diluted share for the quarter ended June 30, 2009.  Net operating
income increased 6.8% to $38.9 million, or 58.3% of net sales, for the
quarter ended June 30, 2010 as compared to net operating income of $36.4
million, or 56.1% of net sales, for the quarter ended June 30, 2009. The
increase in net operating income for the quarter was primarily due to
increased sales and improved gross margins as a result of changes in sales
mix. The increased sales and improved gross margins for the quarter were
partially offset by foreign exchange transaction losses. For the quarter
ended June 30, 2010, foreign exchange transaction losses were $631,000
compared to foreign exchange transaction gains of $685,000 for the quarter
ended June 30, 2009, resulting in a $.03 earnings per share impact between
the quarters ended June 30 2010 and 2009.

For fiscal 2010, Techne's consolidated net earnings increased 4.3% to $110
million or $2.94 per diluted share compared with $105 million or $2.78 per
diluted share for fiscal 2009.  Net operating income increased 3.7% to $156.3
million, or 58.1% of net sales, for fiscal 2010 as compared to net operating
income of $150.8 million, or 57.1% of net sales, for fiscal 2009.  The
increase in net operating income for the fiscal year was primarily due to
increased sales and improved gross margins as a result of changes in sales
mix.  The increased sales and improved gross margins for the fiscal year were
partially offset by lower interest income of $3.3 million, or $.07 per share,
and greater foreign exchange transaction losses of $926,000, or $.02 per
share. Income taxes for fiscal 2010 included a $4.7 million tax benefit in
the third quarter of fiscal 2010.  The tax benefit, equating to $.12 per
share, resulted from a foreign currency exchange tax loss on the repatriation
of 50 million British pound sterling from R&D Europe to the U.S.  Techne
previously paid U.S. income taxes on the foreign earnings that were included
in the repatriated funds.

Consolidated net sales for the quarter and fiscal year ended June 30, 2010
were $66.7 million and $269.0 million, respectively. This was a 2.8% and 1.9%
increase from the quarter and fiscal year ended June 30, 2009, respectively.
Consolidated net sales for the quarter ended June 30, 2010 were negatively
affected by a stronger U.S. dollar as compared foreign currencies (primarily
British pound sterling and euro) for the quarter ended June 30, 2009.
Excluding the effect of changes in foreign currency exchange rates,
consolidated net sales increased 5.4% and 1.6% for the quarter and fiscal
year ended June 30, 2010, respectively, from the comparable prior-year
periods.

Biotechnology net sales, which include sales by R&D Systems' Biotechnology
Division, R&D Systems China and BiosPacific, were $45.3 million for the
quarter ended June 30, 2010, an increase of 7.0% from $42.3 million for the
quarter ended June 30, 2009.  North American biotechnology sales to
industrial pharmaceutical and biotechnology customers increased 11.7% during
the fourth quarter of fiscal 2010 as compared to the fourth quarter of fiscal
2009.  Biotechnology sales to academic customers, Pacific Rim distributors
and sales in China grew 4.3%, 10.0% and 24.8%, respectively, in the fourth
quarter of fiscal 2010 as compared to the fourth quarter of fiscal 2009.

Biotechnology sales were $178 million for fiscal 2010, an increase of 2.3%
over the same period last year. North American biotechnology sales to
industrial pharmaceutical and biotechnology customers increased 0.9% during
fiscal 2010 as compared to fiscal 2009.  Biotechnology sales to academic
customers, Pacific Rim distributors and sales in China grew 4.0%, 10.5% and
21.8%, respectively, in fiscal 2010 as compared to fiscal 2009.

R&D Europe's net sales for the quarter and fiscal year ended June 30, 2010
were $17.0 million and $72.8 million, respectively, a decrease of 5.7% and an
increase of 0.3% from the same prior-year periods.  R&D Europe's net sales
increased 3.8% and decreased 0.9%, respectively, for the quarter and fiscal
year ended June 30, 2010 when measured at currency rates in effect in the
comparable prior periods.

Hematology net sales for the quarter and fiscal year ended June 30, 2010 were
$4.5 million and $18.4 million, a decrease of 2.2% and an increase of 5.1%,
respectively, from comparable prior-year periods.

Consolidated gross margins were 79.3% and 79.8% for the quarter and fiscal
year ended June 30, 2010, respectively, compared to 77.4% and 79.0% for the
quarter and fiscal year ended June 30, 2009, respectively. The increased
gross margins in fiscal 2010 are mainly the result of improved margins in the
biotechnology segment due to incremental profit on increased sales volumes.

Selling, general and administrative expenses for the quarter and fiscal year
ended June 30, 2010 decreased $96,000 (1.3%) and $989,000 (3.0%),
respectively from the quarter and fiscal year ended June 30, 2009. The
decrease in selling, general and administrative expense for the quarter ended
June 30, 2010 resulted primarily from decreased legal expenses of $506,000,
partially offset by annual wage, salary and benefit increases. The decrease
in selling, general and administrative expenses for fiscal 2010 was primarily
due to lower stock compensation ($343,000), profit sharing ($403,000) and
legal ($690,000) expenses, partially offset by annual wage, salary and
benefit increases.

Research and development expenses for the quarter and fiscal year ended June
30, 2010 increased $252,000 (4.2%) and $1.6 million (6.6%), respectively,
from the quarter and fiscal year ended June 30, 2009.  The increase in
research and development expenses is the result of continuous development and
release of new high-quality biotechnology products upon which the Company's
future sales revenue growth is dependent.

Interest income decreased $26,000 and $3.3 million for the quarter and fiscal
year ended June 30, 2010, respectively, from the comparable prior-year
periods, primarily as a result of lower rates of return on cash and
available-for-sale investments, offset in part by higher cash and available-
for-sale investment balances.

The effective tax rates for the quarter and fiscal year ended June 30, 2010
were 32.9% and 29.8%, respectively, as compared to 32.2% and 32.3% for the
same prior-year periods. The effective tax rate for fiscal 2010 was
abnormally low due to the tax benefit received following repatriation of
funds from the U.K. to the U.S. in the third quarter of fiscal 2010.
Excluding this benefit, the effective tax rate for fiscal 2010 would have
been 32.8%.

The Company repurchased 260,693 and 283,555 shares of its common stock during
the quarter and fiscal year ended June 30, 2010, respectively, for
approximately $15.5 million and $16.9 million. Approximately $50.6 million
remains available for the repurchase and retirement of shares under the
currently open authorization.


Forward Looking Statements:

Our press releases may contain forward-looking statements within the meaning
of the Private Litigation Reform Act. Such statements involve risks and
uncertainties that may affect the actual results of operations. The following
important factors, among others, have affected and, in the future, could
affect the Company's actual results: the introduction and acceptance of new
biotechnology and hematology products, the levels and particular directions
of research by the Company's customers, the impact of the growing number of
producers of biotechnology research products and related price competition,
general economic conditions, the retention of hematology OEM and proficiency
survey business, the impact of currency exchange rate fluctuations, and the
costs and results of research and product development efforts of the Company
and of companies in which the Company has invested or with which it has
formed strategic relationships.

For additional information concerning such factors, see the Company's annual
report on Form 10-K and quarterly reports on Form 10-Q as filed with the
Securities and Exchange Commission.  We undertake no obligation to update or
revise any forward-looking statements we make in our press releases due to
new information or future events.  Investors are cautioned not to place undue
emphasis on these statements.

                   *  *  *  *  *  *  *  *  *  *  *  *

Techne Corporation has two operating subsidiaries:  Research and Diagnostic
Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe,
Ltd. (R&D Europe) of Abingdon, England.  R&D Systems is a specialty
manufacturer of biological products.  R&D Systems has two subsidiaries,
BiosPacific, Inc. (BiosPacific), located in Emeryville, California and R&D
Systems China Co. Ltd., (R&D China), located in Shanghai, China.  BiosPacific
is a worldwide supplier of biologics to manufacturers of in vitro diagnostic
systems and immunodiagnostic kits. R&D China and R&D Europe distribute
biotechnology products.


Contact:  Greg Melsen, Chief Financial Officer
          Kathy Backes, Controller
          (612) 379-8854


                           TECHNE CORPORATION
                 CONSOLIDATED STATEMENTS OF EARNINGS
                   (In thousands, except per share data)
                                (Unaudited)

                                       QUARTER ENDED    FISCAL YEAR ENDED
                                     ----------------  ------------------
                                     6/30/10  6/30/09   6/30/10   6/30/09
                                     -------  -------  --------  --------
Net sales                            $66,714  $64,890  $269,047  $263,956
Cost of sales                         13,834   14,656    54,463    55,488
                                     -------  -------  --------  --------
Gross margin                          52,880   50,234   214,584   208,468
                                     -------  -------  --------  --------
 Operating expenses:
  Selling, general and administrative  7,464    7,560    32,175    33,164
  Research and development             6,251    5,999    25,121    23,564
  Amortization of intangible assets      240      240       960       960
                                     -------  -------  --------  --------
   Total operating expenses           13,955   13,799    58,256    57,688
                                     -------  -------  --------  --------
Operating income                      38,925   36,435   156,328   150,780
Other income (expense):
  Interest income                      1,011    1,038     4,375     7,634
  Other non-operating expense, net    (1,335)     (49)   (4,257)   (3,051)
                                     -------  -------  --------  --------
   Total other (expense) income         (324)     989       118     4,583
                                     -------  -------  --------  --------
Earnings before income taxes          38,601   37,424   156,446   155,363
Income taxes                          12,706   12,038    46,670    50,121
                                     -------  -------  --------  --------
Net earnings                         $25,895  $25,386  $109,776  $105,242
                                     =======  =======  ========  ========
Earnings per share:
 Basic                               $  0.70  $  0.68  $   2.95  $   2.78
 Diluted                             $  0.69  $  0.68  $   2.94  $   2.78

Weighted average common
 shares outstanding:
  Basic                               37,233   37,248    37,255    37,802
  Diluted                             37,314   37,332    37,347    37,900


                             TECHNE CORPORATION
                         CONSOLIDATED BALANCE SHEETS
                                 (In thousands)
                                  (Unaudited)
                                                     6/30/10    6/30/09
                                                    --------   --------
ASSETS
Cash and equivalents                                $ 98,925   $160,940
Short-term available-for-sale investments             39,886     41,947
Trade accounts receivable                             30,850     29,516
Other receivables                                      1,532      1,637
Inventory                                             13,737     11,269
Other current assets                                  16,110     10,158
                                                    --------   --------
  Current assets                                     201,040    255,467

Available-for-sale investments                       171,171     61,863
Property and equipment, net                           97,400    100,133
Goodwill and intangible assets, net                   27,112     28,072
Other non-current assets                              22,093     26,470
                                                    --------   --------
  Total assets                                      $518,816   $472,005
                                                    ========   ========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities                                 $ 17,024   $ 15,523
Stockholders' equity                                 501,792    456,482
                                                    --------   --------
  Total liabilities and stockholders' equity        $518,816   $472,005
                                                    ========   ========



</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>segment610.txt
<DESCRIPTION>SEGMENT RESULTS
<TEXT>
                                  SEGMENT INFORMATION
                        TECHNE CORPORATION AND SUBISIDARIES
                    (in thousands of $'s, except per share data)

<CAPTION>
<TABLE>

                                Fiscal 2010                        Increase (Decrease) From Fiscal 2009
               ------------------------------------------------- ---------------------------------------
                First  Second   Third  Fourth           Percent   First  Second   Third  Fourth
               Quarter Quarter Quarter Quarter   YTD    Of Sales Quarter Quarter Quarter Quarter   YTD
               ------- ------- ------- ------- -------- -------- ------- ------- ------- ------- -------
<S>            <C>     <C>     <C>     <C>     <C>      <C>      <C>     <C>     <C>     <C>     <C>
Sales           66,534  65,521  70,278  66,714  269,047   100%    (2,790)  3,645   2,412   1,824   5,091
Cost of sales   12,901  13,329  14,399  13,834   54,463    20%      (185)   (101)     83    (822) (1,025)
               ------- ------- ------- ------- -------- -------- ------- ------- ------- ------- -------
Gross margin    53,633  52,192  55,879  52,880  214,584    80%    (2,605)  3,746   2,329   2,646   6,116

Gross margin
 percentage      80.6%   79.7%   79.5%   79.3%    79.8%

SG&A expense     8,038   9,007   7,666   7,464   32,175    12%      (802)   (696)    605     (96)   (989)
R&D expense      6,154   6,391   6,325   6,251   25,121    10%       244     545     516     252   1,557
Amortization
 expense           240     240     240     240      960     --        --      --      --      --      --
Interest income (1,168) (1,156) (1,040) (1,011)  (4,375)   (2%)    1,719   1,049     464      27   3,259
Other non-oper-
 ating ex., net    662   1,011   1,249   1,335    4,257     2%      (525)    299     146   1,286   1,206
               ------- ------- ------- ------- -------- -------- ------- ------- ------- ------- -------
                13,926  15,493  14,440  14,279   58,138    22%       636   1,197   1,731   1,469   5,033
               ------- ------- ------- ------- -------- -------- ------- ------- ------- ------- -------
Earnings before
 income taxes   39,707  36,699  41,439  38,601  156,446    58%    (3,241)  2,549     598   1,177   1,083
Income taxes    12,935  11,978   9,051  12,706   46,670    17%    (1,420)  1,450  (4,149)    668  (3,451)
               ------- ------- ------- ------- -------- -------- ------- ------- ------- ------- -------
                26,772  24,721  32,388  25,895  109,776    41%    (1,821)  1,099   4,747     509   4,534
               ======= ======= ======= ======= ======== ======== ======= ======= ======= ======= =======

Diluted earnings
 per share         .72     .66     .87     .69     2.94
Weighted average
 diluted shares
 outstanding    37,339  37,353  37,380  37,314   37,347

</TABLE>



                                      BIOTECHNOLOGY  (1)
                                    (in thousands of $'s)
<CAPTION>
<TABLE>

                                Fiscal 2010                        Increase (Decrease) From Fiscal 2009
               ------------------------------------------------- ---------------------------------------
                First  Second   Third  Fourth           Percent   First  Second   Third  Fourth
               Quarter Quarter Quarter Quarter   YTD    Of Sales Quarter Quarter Quarter Quarter   YTD
               ------- ------- ------- ------- -------- -------- ------- ------- ------- ------- -------
<S>            <C>     <C>     <C>     <C>     <C>      <C>      <C>     <C>     <C>     <C>     <C>
Sales           51,696  50,703  54,236  53,032  209,667   100%    (2,203)  2,060     518   3,298   3,673
Intersegment
 sales          (7,668) (8,282) (8,057) (7,771) (31,778)              94      29     522    (342)    303
               ------- ------- ------- ------- -------- -------- ------- ------- ------- ------- -------
                44,028  42,421  46,179  45,261  177,889           (2,109)  2,089   1,040   2,956   3,976

Cost of sales    9,885  10,126  11,159  10,569   41,739    20%      (362)   (964)     79     258    (989)
Intersegment
 sales          (7,598) (7,753) (8,336) (7,857) (31,544)            (137)    586     158    (403)    204
               ------- ------- ------- ------- -------- -------- ------- ------- ------- ------- -------
                 2,287   2,373   2,823   2,712   10,195             (499)   (378)    237    (145)   (785)

Gross margin    41,741  40,048  43,356  42,549  167,694    80%    (1,610)  2,467     803   3,101   4,761

Gross margin
 percentage      80.9%   80.0%   79.4%   80.1%    80.1%

SG&A expense     4,734   5,056   4,625   4,532   18,947     9%      (407)   (362)    363     318     (88)
R&D expense      5,956   6,190   6,127   6,058   24,331    12%       239     547     505     248   1,539
Amortization
 expense           240     240     240     240      960     --        --      --      --      --      --
Interest, net     (771)   (772)   (706)   (733)  (2,982)   (1%)      313     198     147      10     668
Other expense        2       1      --      (2)       1     --         4      --      (1)     (4)     (1)
               ------- ------- ------- ------- -------- -------- ------- ------- ------- ------- -------
                10,161  10,715  10,286  10,095   41,257    20%       149     383   1,014     572   2,118
               ------- ------- ------- ------- -------- -------- ------- ------- ------- ------- -------
Pretax result   31,580  29,333  33,070  32,454  126,437    60%    (1,759)  2,084    (211)  2,529   2,643
               ======= ======= ======= ======= ======== ======== ======= ======= ======= ======= =======

</TABLE>

(1)	Includes R&D Systems' Biotechnology Division, BiosPacific, Inc.
and R&D China


                                      R&D SYSTEMS EUROPE
                                 (in thousands of Br. pounds)
<CAPTION>
<TABLE>

                                Fiscal 2010                        Increase (Decrease) From Fiscal 2009
               ------------------------------------------------- ---------------------------------------
                First  Second   Third  Fourth           Percent   First  Second   Third  Fourth
               Quarter Quarter Quarter Quarter   YTD    Of Sales Quarter Quarter Quarter Quarter   YTD
               ------- ------- ------- ------- -------- -------- ------- ------- ------- ------- -------
<S>            <C>     <C>     <C>     <C>     <C>      <C>      <C>     <C>     <C>     <C>     <C>
Sales           10,881  11,462  12,296  11,403   46,042    100%      706     265    (420)    269     820
Cost of sales    5,061   5,288   5,824   5,785   21,958     48%      801     (73)   (716)    102     114
               ------- ------- ------- ------- -------- -------- ------- ------- ------- ------- -------
Gross margin     5,820   6,174   6,472   5,618   24,084     52%      (95)    338     296     167     706

Gross margin
 percentage      53.5%   53.9%   52.6%   49.3%    52.3%

SG&A expense     1,191   1,318   1,260   1,315    5,084     11%      (33)    (46)     69     127     117
Interest income    (87)    (79)    (68)    (38)    (272)     --      703     504     167      64   1,438
Exchange loss/
 (gain)            (89)     61     237     428      637      1%     (349)     96      74     796     617
               ------- ------- ------- ------- -------- -------- ------- ------- ------- ------- -------
                 1,015   1,300   1,429   1,705    5,449     12%      321     554     310     987   2,172
               ------- ------- ------- ------- -------- -------- ------- ------- ------- ------- -------
Pretax result    4,805   4,874   5,043   3,913   18,635     40%     (416)   (216)    (14)   (820) (1,466)
               ======= ======= ======= ======= ======== ======== ======= ======= ======= ======= =======

</TABLE>



                                      R&D SYSTEMS EUROPE
                                     (in thousands of $'s)
<CAPTION>
<TABLE>

                                Fiscal 2010                        Increase (Decrease) From Fiscal 2009
               ------------------------------------------------- ---------------------------------------
                First  Second   Third  Fourth           Percent   First  Second   Third  Fourth
               Quarter Quarter Quarter Quarter   YTD    Of Sales Quarter Quarter Quarter Quarter   YTD
               ------- ------- ------- ------- -------- -------- ------- ------- ------- ------- -------
<S>            <C>     <C>     <C>     <C>     <C>      <C>      <C>     <C>     <C>     <C>     <C>
Sales           17,838  18,775  19,161  16,990   72,764    100%   (1,103)  1,491     868  (1,033)    223
Cost of sales    8,295   8,664   9,071   8,619   34,649     48%      364     390    (334)   (811)   (391)
               ------- ------- ------- ------- -------- -------- ------- ------- ------- ------- -------
Gross margin     9,543  10,111  10,090   8,371   38,115     52%   (1,467)  1,101   1,202    (222)    614

Gross margin
 percentage      53.5%   53.9%   52.7%   49.3%    52.4%

SG&A expense     1,952   2,159   1,967   1,961    8,039     11%     (331)     65     253      85      72
Interest income   (143)   (128)   (108)    (57)    (436)     --    1,328     778     230     (29)  2,307
Exchange loss/
 Gain             (145)     99     372     633      959      1%     (621)     94     134   1,320     927
               ------- ------- ------- ------- -------- -------- ------- ------- ------- ------- -------
                 1,664   2,130   2,231   2,537    8,562     12%      376     937     617   1,376   3,306
               ------- ------- ------- ------- -------- -------- ------- ------- ------- ------- -------
Pretax result    7,879   7,981   7,859   5,834   29,553     40%   (1,843)    164     585  (1,598) (2,692)
               ======= ======= ======= ======= ======== ======== ======= ======= ======= ======= =======

</TABLE>

                                             HEMATOLOGY
                                         (in thousands of $'s)
<CAPTION>
<TABLE>

                                Fiscal 2010                        Increase (Decrease) From Fiscal 2009
               ------------------------------------------------- ---------------------------------------
                First  Second   Third  Fourth           Percent   First  Second   Third  Fourth
               Quarter Quarter Quarter Quarter   YTD    Of Sales Quarter Quarter Quarter Quarter   YTD
               ------- ------- ------- ------- -------- -------- ------- ------- ------- ------- -------
<S>            <C>     <C>     <C>     <C>     <C>      <C>      <C>     <C>     <C>     <C>     <C>
Sales            4,668   4,325   4,938   4,463   18,394    100%      422      65     504     (99)    892
Cost of sales    2,319   2,292   2,505   2,503    9,619     52%      (50)   (113)    180     134     151
               ------- ------- ------- ------- -------- -------- ------- ------- ------- ------- -------
Gross margin     2,349   2,033   2,433   1,960    8,775     48%      472     178     324    (233)    741

Gross margin
 percentage      50.3%   47.0%   49.3%   43.9%    47.7%

SG&A expense       370     366     346     311    1,393      8%      (66)    (32)     36      (8)    (70)
R&D expense        198     201     198     193      790      4%        5      (2)     11       4      18
Interest, net      (72)    (72)    (65)    (68)    (277)    (1%)      30      19      15       4      68
               ------- ------- ------- ------- -------- -------- ------- ------- ------- ------- -------
                   496     495     479     436    1,906     11%      (31)    (15)     62       0      16
               ------- ------- ------- ------- -------- -------- ------- ------- ------- ------- -------
Pretax result    1,853   1,538   1,954   1,524    6,869     37%      503     193     262    (233)    725
               ======= ======= ======= ======= ======== ======== ======= ======= ======= ======= =======

</TABLE>



                                  CORPORATE AND OTHER (2)
                                    (in thousands of $'s)
<CAPTION>
<TABLE>

                                Fiscal 2010               Increase (Decrease) From Fiscal 2009
               ---------------------------------------- ---------------------------------------
                First  Second   Third  Fourth           First  Second   Third  Fourth
               Quarter Quarter Quarter Quarter   YTD    Quarter Quarter Quarter Quarter   YTD
               ------- ------- ------- ------- -------- ------- ------- ------- ------- -------
<S>            <C>     <C>     <C>     <C>     <C>      <C>     <C>     <C>     <C>     <C>
Interest income    182     184     161     153      680     (48)    (54)    (72)    (42)   (216)
Rental income       81     115      83     134      413     (18)    (16)    (32)     (2)    (68)
               ------- ------- ------- ------- -------- ------- ------- ------- ------- -------
                   263     299     244     287    1,093     (66)    (70)   (104)    (44)   (284)

SG&A expense       982   1,426     728     660    3,796       2    (367)    (47)   (491)   (903)
Other-Building
 expenses          548     530     593     529    2,200      (5)    (21)     20      (2)     (8)
Other-Equity
 Investment
  losses           338     496     367     309    1,510      79     210     (39)    (30)    220
               ------- ------- ------- ------- -------- ------- ------- ------- ------- -------
                 1,868   2,452   1,688   1,498    7,506      76    (178)    (66)   (523)   (691)
               ------- ------- ------- ------- -------- ------- ------- ------- ------- -------
Pretax result   (1,605) (2,153) (1,444) (1,211)  (6,413)   (142)    108     (38)    479     407
               ======= ======= ======= ======= ======== ======= ======= ======= ======= =======
</TABLE>


(2) Unallocated corporate expenses and Techne's share of
losses by Hemerus Medical, LLC and Nephromics, LLC.
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
